Hjem › Myelodysplastiske syndromer › Ohio › Columbus
Myelodysplastiske syndromer kliniske forsøg i Columbus, OH
14 studier for Myelodysplastiske syndromer søger deltagere på steder i og omkring Columbus (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekruttererFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RekruttererFase 1/2
- The Ohio State University, Columbus
Collection of Tissue Samples for Cancer Research
RekruttererObservationsstudie
- Ohio State University, Columbus
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
RekruttererFase 1
- Ohio State University, The James Comprehensive Cancer, Columbus
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
RekruttererFase 3
- Ohio State University Comprehensive Cancer Center, Columbus
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekruttererFase 1/2
- Nationwide Children's Hospital, Columbus
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
RekruttererFase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RekruttererFase 2/3
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
RekruttererFase 1
- Ohio State University Medical Center, Columbus
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RekruttererFase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservationsstudie
- Massive Bio SYNERGY-AI site, Columbus
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RekruttererFase 1
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
HPC Offered for PRESERVE Expansion
RekruttererObservationsstudie
- The Ohio State University Medical Center, Columbus
Myelodysplastiske syndromer forsøg i andre byer
- Houston, TX43 studier
- Baldwin Park, CA26 studier
- New York City, NY21 studier
- Seattle, WA21 studier
- Washington, DC20 studier
- Boston, MA19 studier
- Tampa, FL19 studier
- Miami, FL17 studier
- Durham, NC14 studier
- Chicago, IL13 studier
- Atlanta, GA13 studier
- St. Louis, MO13 studier
Andre studier i Columbus
- Ikke-småcellet lungecancer56 studier
- Brystkræft39 studier
- Ægstockræft39 studier
- Kræft (alle typer)38 studier
- Lungecancer37 studier
- Akut myeloid leukæmi35 studier
- Kronisk lymfatisk leukæmi28 studier
- Metastatisk cancer27 studier
- Livmoderslimhindekræft25 studier
- Colorektal kræft24 studier
- Prostatakræft24 studier
- Multipelt myelom24 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.